Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and immunogenicity study of Ag85B-ESAT-6 + IC31 TB subunit vaccine in PPD-positive adults
NL-OMON30684Phase 1Active, not recruiting
- Sponsor
- Statens Serum Institut
- Start
- Nov 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ag85B-ESAT-6 + IC31 in Tuberculosis (TB) (2 cohorts), sponsored by Statens Serum Institut. Primary endpoints: Safety by physical examination, Local and systemic adverse events and 2 more. Started Nov 2007; status: active, not recruiting.
02
Drugs
Ag85B-ESAT-6 + IC31
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON30684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30684.